Something to think about. Insurance carriers have also set up shop in China as well. All developments in R and D are no longer being controlled here in the US.
Even technology companies such as Microsoft are now depending more upon the technology being developed at their offices located in China. This article has a few examples and I have added some additional links under related reading to tell a bit more about how things are shifting outside the US, some are partnerships with other countries as well working with the US. Recently in the news the FDA accepted statistics from a research company in China versus coming from the US, so one sign of the times that things are changing around us rapidly. BD
The theme of innovation dominated the China biopharma news last week. Most significantly, Thomson Reuters predicted that China will be the world's leading technology innovator by 2012 (see story). The company looked at trends in patent filings (and patent awards) and extrapolated the trends forward to make the prediction. Currently, China occupies the number three spot. However, in terms of growth, it far outpaces its rivals. During the period 2002-2007, China's patent filings grew at an annual rate of 34%. Next best was the U.S. at a paltry 13%. But even the U.S.'s performance is better than Japan's, which actually dropped at an average of 3% per year. Thomson Reuters' report credited China's central government policies for advancing the country's economy beyond its traditional focus on agriculture and manufacturing.
RHEI Pharmaceuticals has begun the final China clinical trial for Tibozole, a locally active antifungal with low dose miconazole in a patented mucoadhesive system (see story).
BioDuro, a CRO headquartered in San Diego, CA, but with its laboratories in Beijing, China, announced that it has been awarded full accreditation from the Association for Assessment and Accreditation of Laboratory Animal Care International ((AAALAC)) (see story)
Cook Medical, a privately owned medical device company located in Bloomington IN, will open a combined distribution and customer service center in Shanghai (see story).
China Shenghuo Pharmaceutical Holdings (KUN) has resumed trading (see story). The company's stock was suspended from trading in late August because China Shenghuo was late in filing its financial statements